Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCGO NASDAQ:NAKA NASDAQ:VMD NASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCGODocGo$1.33-2.2%$1.50$1.23▼$5.68$138.70M0.97459,240 shs568,763 shsNAKAKindlyMD$6.35-12.0%$0.00$0.65▼$34.77$52.74M35.16284,191 shs569,030 shsVMDViemed Healthcare$5.93-2.6%$6.67$5.93▼$9.81$240.70M1.34220,438 shs296,959 shsXGNExagen$8.63+2.7%$7.19$1.78▼$9.10$184.83M1.61428,131 shs282,684 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCGODocGo-2.21%-8.90%-15.29%-42.42%-63.36%NAKAKindlyMD-12.05%-42.11%-51.60%+634,999,900.00%+634,999,900.00%VMDViemed Healthcare-2.63%-3.10%-16.24%-19.54%-17.75%XGNExagen+2.74%+18.71%+23.82%+43.36%+342.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCGODocGo2.9198 of 5 stars3.33.00.00.03.22.50.6NAKAKindlyMDN/AN/AN/AN/AN/AN/AN/AN/AVMDViemed Healthcare2.8844 of 5 stars0.05.00.00.02.93.31.3XGNExagen4.5404 of 5 stars4.52.00.04.52.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCGODocGo 2.50Moderate Buy$3.56167.67% UpsideNAKAKindlyMD 0.00N/AN/AN/AVMDViemed Healthcare 0.00N/AN/AN/AXGNExagen 3.00Buy$11.2530.36% UpsideCurrent Analyst Ratings BreakdownLatest NAKA, VMD, XGN, and DCGO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025XGNExagenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.007/30/2025XGNExagenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $11.007/30/2025XGNExagenKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSector Weight ➝ Overweight$12.007/23/2025XGNExagenCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.005/15/2025XGNExagenUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025XGNExagenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.005/13/2025XGNExagenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/12/2025DCGODocGoCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$5.00 ➝ $1.455/9/2025DCGODocGoNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.005/9/2025DCGODocGoBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/7/2025XGNExagenBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCGODocGo$520.50M0.26$0.41 per share3.22$3.09 per share0.43NAKAKindlyMD$2.47M18.78N/AN/A$0.43 per share14.77VMDViemed Healthcare$224.26M1.05$0.92 per share6.47$3.41 per share1.74XGNExagen$55.64M3.41N/AN/A$0.96 per share8.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCGODocGo$19.99M-$0.02N/A16.63N/A-0.12%2.52%1.70%8/7/2025 (Estimated)NAKAKindlyMD-$3.62M-$0.77N/A∞N/A-177.01%-146.26%-109.19%N/AVMDViemed Healthcare$11.27M$0.3019.77∞N/A5.28%9.49%7.14%8/6/2025 (Estimated)XGNExagen-$15.11M-$0.89N/AN/AN/A-28.85%-130.38%-34.69%N/ALatest NAKA, VMD, XGN, and DCGO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025DCGODocGo-$0.06N/AN/AN/A$77.58 millionN/A7/29/2025Q2 2025XGNExagen-$0.18-$0.18N/A-$0.21$16.25 million$17.20 million5/12/2025Q1 2025XGNExagen-$0.20-$0.20N/A-$0.20$14.55 million$15.50 million5/8/2025Q1 2025DCGODocGo-$0.01-$0.09-$0.08-$0.09$104.25 million$96.03 million5/7/2025Q1 2025VMDViemed Healthcare$0.06$0.06N/A$0.06$60.60 million$59.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCGODocGoN/AN/AN/AN/AN/ANAKAKindlyMDN/AN/AN/AN/AN/AVMDViemed HealthcareN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCGODocGoN/A2.442.44NAKAKindlyMDN/A2.302.30VMDViemed Healthcare0.031.381.26XGNExagen1.064.952.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCGODocGo56.44%NAKAKindlyMDN/AVMDViemed Healthcare74.24%XGNExagen75.25%Insider OwnershipCompanyInsider OwnershipDCGODocGo2.70%NAKAKindlyMD40.79%VMDViemed Healthcare20.00%XGNExagen12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCGODocGo4,407101.98 million99.23 millionOptionableNAKAKindlyMDN/A7.31 million4.33 millionN/AVMDViemed Healthcare1,17939.52 million31.62 millionNot OptionableXGNExagen22022.00 million19.23 millionOptionableNAKA, VMD, XGN, and DCGO HeadlinesRecent News About These CompaniesFY2026 EPS Estimates for Exagen Cut by Cantor FitzgeraldAugust 2 at 7:25 AM | marketbeat.comWilliam Blair Has Negative Outlook of Exagen FY2025 EarningsAugust 2 at 6:23 AM | marketbeat.comWhat is KeyCorp's Forecast for Exagen Q3 Earnings?August 2 at 5:35 AM | marketbeat.comFY2025 Earnings Forecast for Exagen Issued By William BlairAugust 2 at 2:49 AM | americanbankingnews.comKeyCorp Predicts Exagen's Q3 Earnings (NASDAQ:XGN)August 2 at 2:25 AM | americanbankingnews.comExagen (XGN) Receives a Buy from Craig-HallumAugust 1 at 11:21 PM | theglobeandmail.comFY2026 Earnings Forecast for Exagen Issued By KeyCorpAugust 1 at 7:00 AM | marketbeat.comExagen Inc. Reports Record Revenue Amidst Growth ChallengesAugust 1 at 5:15 AM | theglobeandmail.comCanaccord Genuity Group Raises Exagen (NASDAQ:XGN) Price Target to $11.00August 1 at 3:43 AM | americanbankingnews.comExagen (NASDAQ:XGN) Upgraded at KeyCorpAugust 1 at 2:16 AM | americanbankingnews.comCanaccord Genuity Sticks to Its Buy Rating for Exagen (XGN)July 31 at 12:14 AM | theglobeandmail.comExagen (NASDAQ:XGN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst SaysJuly 31 at 8:29 AM | marketbeat.comExagen (NASDAQ:XGN) Upgraded to "Overweight" at KeyCorpJuly 31 at 8:03 AM | marketbeat.comXGN | Exagen Inc. Annual Cash Flow Statement | MarketWatchJuly 31 at 2:20 AM | marketwatch.comKeybanc Upgrades Exagen (XGN)July 31 at 2:20 AM | msn.comExagen (NASDAQ:XGN) Posts Earnings Results, Hits EstimatesJuly 30 at 9:18 AM | marketbeat.comExagen upgraded to Overweight from Sector Weight at KeyBancJuly 30 at 8:06 AM | msn.comExagen Q2 Revenue Jumps 14 PercentJuly 29, 2025 | aol.comAExagen Inc. (XGN) Q2 2025 Earnings Call TranscriptJuly 29, 2025 | seekingalpha.comExagen Inc. (XGN) Reports Q2 Loss, Beats Revenue EstimatesJuly 29, 2025 | zacks.comExagen Inc. Reports Strong Q2 2025 ResultsJuly 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNAKA, VMD, XGN, and DCGO Company DescriptionsDocGo NASDAQ:DCGO$1.33 -0.03 (-2.21%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.32 -0.01 (-0.38%) As of 08/1/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.KindlyMD NASDAQ:NAKA$6.35 -0.87 (-12.05%) As of 08/1/2025 04:00 PM EasternKindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.Viemed Healthcare NASDAQ:VMD$5.93 -0.16 (-2.63%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$5.93 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.Exagen NASDAQ:XGN$8.63 +0.23 (+2.74%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$8.03 -0.60 (-6.95%) As of 08/1/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
